Study of Immunotherapy for Prevention and Care of Infectious Diseases and Primary Liver Tumors

What this Trial Is About

This research focuses on two main areas related to immunotherapy for infectious and tumor diseases. The first area involves generating human monoclonal antibodies against SARS-CoV-2 and testing their function in the lab. The second area evaluates the immune response of antibodies directed at specific tumor molecules, particularly in patients with primary liver tumors. The study is observational and includes adults aged 18 to 90 years who have recovered from SARS-CoV-2 or have liver tumors. Participants fall into two groups those recovered from SARS-CoV-2 infection and patients with primary liver tumors. Researchers will perform laboratory tests to assess the effectiveness of antibodies against the virus and liver tumor cells. The study monitors the antibody efficiency from enrollment up to 24 weeks, focusing on in vitro functional tests. During the study, participants will undergo blood tests and other laboratory evaluations to analyze their immune response. Researchers will measure how well antibodies work against SARS-CoV-2 and liver tumor cells. The study also tracks safety and other health factors over time. Participants involvement could last up to 24 weeks, with assessments carried out during this period to understand antibody activity and immune function.

Immunotherapy: Care and Prevention of Infectious and Tumoral Diseases (ImmunoHUB)